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Background: Chronic obstructive pulmonary disease (COPD) is marked by de-
struction of alveolar architecture. Preclinical modelling for COPD is challenging. 
Chronic cigarette smoke exposure, the reference animal model of COPD, is 
time-inefficient, while exposure to waterpipe smoke (WPS), a surging smoking 
modality, was not fully tested for its histopathological pulmonary consequences. 
Since alveolar damage and pulmonary vascular endothelial dysfunction are integral 
to COPD pathology, lung histopathological effects of WPS were temporally eva-
luated, alone or in combination with vascular endothelial growth factor receptor 
(VEGFR) inhibition in mice.
Materials and methods: Mice were exposed to WPS, 3 hours/day, 5 days/week, 
for 1, 2, 3, or 4 months. Another group of mice was exposed to WPS for 1 month, 
while being subjected to injections with the VEGFR blocker Sugen5416 (SU, 
20 mg/kg) 3 times weekly. Control mice were exposed to fresh air in a matching 
inhalation chamber. Histopathological assessment of COPD was performed. Alve-
olar destructive index (DI) was counted as the percentage of abnormally enlarged 
alveoli with damaged septa per all alveoli counted. Mean linear intercept (MLI) 
was calculated as a measure of airspace enlargement.
Results: Exposure to WPS resulted in significant increases in alveolar DI and MLI 
only after 4 months. Lung inflammatory score was minimal across all time-points. 
Importantly, combination of WPS and SU resulted in significantly increased DI, 
MLI, and inflammatory scores as early as 1 month post exposure.
Conclusions: Combined exposure to WPS and SU results in COPD picture, 
highlighting the role of pulmonary vascular endothelial dysfunction in the disease. 
(Folia Morphol 2018; 77, 3: 447–455)
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is 
characterised by progressive airflow limitation, fre-
quently complicated by acute exacerbations [4]. Smok-
ing is conceivably the principal cause of the disease [36]. 
COPD is projected to be the third leading cause of death 
and the fifth leading cause of disability globally by the 
year 2020, harbouring massive health and economic 
burdens worldwide [1]. The past few decades registered 
significant advancements in our understanding of the 
pathology of COPD. However, such basic knowledge 
was not clinically translated into novel biomarkers of 
disease progression and/or treatment modalities [7, 9].
The unfortunate gap in translational science in the 
field of COPD prognostics and therapeutics is largely 
attributed to the inadequacy of the available preclini-
cal models of the disease, as they fail to recapitulate 
the major features of COPD in terms of pathology 
and natural history [45]. The reference animal model 
of COPD is the chronic cigarette smoke exposure in 
rodents. However, these animals do not develop the 
severe disabling disease seen in humans, as the major 
structural and functional consequences do not ap-
pear to progress after cessation of smoke exposure 
[6, 10]. More importantly, rodents require several 
months of exposure to cigarettes to develop some of 
the basic features of mild-moderate COPD, highlight-
ing the time and cost inefficiency of this model [46]. 
In this regard, the effect of waterpipe smoking, as 
a distinct modality of tobacco smoke exposure, was 
never examined, despite the well-documented dif-
ferences in toxicant composition and effect between 
cigarettes and waterpipe [12, 34]. Recent reports have 
signified the alarming upsurge in the frequency of 
waterpipe smoking worldwide [28, 29], necessitating 
more focused research on its unidentified pulmonary 
consequences [14].  
Historically, chronic airway inflammation that is in-
jurious to pulmonary epithelial cells was placed in the 
core of COPD pathogenesis [25]. End-stage disease 
results also in increased pulmonary vascular resist-
ance, pulmonary hypertension, and right heart failure 
[2, 3]. In this classical schema, pulmonary vascular 
endothelial damage is seen secondary to the severe 
“primary” airway disease. However, recent reports 
have shown that several measures of the systemic 
and pulmonary micro- and macrovascular functions 
are impaired even in early-stage COPD [38]. Further-
more, modelling for pulmonary vascular diseases, 
via inhibition of the vascular endothelial growth fac-
tor (VEGF) signalling, traditionally induces COPD-like 
lung pathology [19]. Interestingly, cigarette smoke 
exposure was found to interrupt VEGF signalling in 
rat lungs and in lungs of COPD patients [26]. 
Based on this background, the following research 
question was raised: does the combined and simul-
taneous exposure to chronic waterpipe smoke (WPS) 
and vascular endothelial dysfunction enhance the in-
duction of COPD in animals? To answer this question, 
temporal evaluation of the histopathological effect 
of whole-body exposure to WPS in mice was firstly 
done. Subsequently, the histopathological effect of 
combined exposure to WPS and the VEGF receptor 
(VEGFR) blocker Sugen5416 (Semaxinib [SU]) was 
evaluated.
MATERIALS AND METHODS
All experimental procedures conformed to the 
National Research Council’s Guide for the Care and 
Use of Laboratory Animals (1996, published by Na-
tional Academy Press, USA) and were approved by 
the Institutional Animal Care and Use Committee at 
Jordan University of Science and Technology.
Animals and experimental groups
Six weeks-old naïve BALB/c mice, weighing around 
25 g each, were used in this study. The animals were 
maintained in the animal care unit at 24 ± 1°C with 
a 12:12 light/dark cycle. Apart from the exposure 
sessions, ear-tagged and labelled mice were caged 
in groups of 4 in plastic cages, and food and water 
were available ad libitum.
Seven experimental groups of mice were studied 
as follows: 
—  A — normal controls (n = 6): mice were placed in 
the inhalation chamber and exposed to fresh air. 
—  B–E — WPS-exposed: mice were placed in the 
inhalation chamber and exposed to WPS 3 hours/ 
/day, 5 days/week, for 1 (B), 2 (C), 3 (D), or 4 (E) 
months (n = 6 for each time point). 
—  F — WPS + SU-exposed (n = 8): mice under-
went the same protocol of WPS exposure for 
1 month, while being subjected to subcutaneous 
injections of the VEGFR blocker SU (20 mg/kg, 
Cayman Chemical, USA) 3 times weekly, based on 
the dosing regimen we and others have reported 
previously [2, 11, 42]. 
—  G — SU alone (n = 4): mice were injected with 
SU (20 mg/kg) 3 times weekly for 1 month and 
exposed to fresh air in the inhalation chamber.
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The inhalation chamber and WPS  
exposure machine
The inhalation chamber used in this study was 
described in full details by our group previously [22]. 
Briefly, the chamber, constructed from transparent 
polycarbonate, had a removable ceiling fitted with 
flow ports for: the WPS inlet, fresh air inlet, excess 
flow outlet, and smoke sampling line. A fan was 
suspended from the lid to ensure that the cham-
ber contents are well-mixed during each exposure 
session. Carbon monoxide (CO) concentration was 
continuously monitored in the chamber using an 
electrochemical sensor (Bacharach Monoxor II, USA), 
drawing a flow rate of 0.3 LPM through a 47 mm glass 
fibre filter (Pall Type A/E). Mean ± standard deviation 
(SD) CO concentration across all exposure sessions 
was found to be 963 ± 71 ppm. Fresh air was continu-
ously pumped into the chamber, for an estimated air 
change rate of approximately 1.5 changes per hour. 
The WPS machine hooked to the chamber was 
a commercially available waterpipe machine that burns 
commercial flavoured tobacco (two-apple ma’assel), 
and utilises a variable flow positive displacement 
diaphragm pump to draw from a waterpipe and 
discharge into the inhalation chamber applying 
a whole-body exposure to smoke. Generally, the smoke 
from the waterpipe passes first through the water 
before it is drawn into the inhalation chamber. Water 
was replaced before each exposure session. The pump 
was automatically controlled to provide 171 puffs of 
2.6 s duration with an inter-puff interval of 17 s, in 
accordance with the Beirut Method [21]. During each 
exposure session, puff volumes were monitored and 
recorded using a waterpipe puff topography instru-
ment, simulating the human puff topography during 
waterpipe smoking, as reported previously [39].
Lung inflation and fixation
At the end of experimental periods, mice were 
sacrificed 12 h after the last WPS exposure session, 
with an overdose of pentobarbital administered in-
traperitoneally. Mice were then placed on a surgical 
pad, and an open chest procedure was performed, 
where lungs were dissected out. Isolated lungs were 
fixed for histological analysis by tracheal instillation 
of a mixture of 1% formalin and 0.5% agarose under 
constant pressure (20 cmH2O). The trachea was li-
gated after sustained inflation, and the lung was then 
immersed in 10% formalin for 48 h. Formalin-fixed 
lung samples were subsequently cut into 5 mm-thick 
sections, placed in 70% ethanol, and embedded in 
paraffin. Paraffin sections (5 µm thick) were then 
serially mounted onto slides and stained with hae-
matoxylin and eosin (H&E) and Periodic acid-Schiff 
(PAS) stains. 
Histopathological analyses of lung samples
Mean linear intercept. Mean linear intercept (MLI) 
in lung samples, a measure of airspace enlargement, 
was examined on two full sections of each lung, as 
previously reported [35]. Using light microscopy, MLI 
was determined on a transparent overlay consisting of 
10 horizontal and 10 vertical lines superimposed over 
H&E stained slides (Fig. 1A). All intercepts with alveolar 
septal walls were counted at the intersection point of 
the two lines. The total length of all the lines together 
divided by the total number of intercepts gives the MLI 
for the region studied. 
Destructive index. Destructive index (DI), a gauge 
of parenchymal destruction [37], was evaluated by 
a microscopic point count technique, using a trans-
parent sheet with 100 counting points laid on micro-
scopic images of H&E stained lungs by three blinded 
observers (Fig. 1B). Two full sections of each lung 
were evaluated. Regions containing large bronchi, 
vessels, collapsed tissue, or extensive fibrosis were 
excluded from counting. Destruction was defined as 
the presence of classic emphysematous changes in 
the form of abnormal enlargement of airspaces distal 
to the terminal bronchioles with destruction of the 
alveolar septa. DI was calculated as the percentage of 
destroyed alveoli of all the alveoli counted per section.
Inflammatory infiltration. Scoring of lung in-
flammatory cell infiltration was performed using the 
system developed for the assessment of inflammation 
in pulmonary hypertension by Stacher et al. [41], with 
some modifications (Fig. 2A). Briefly, the parenchymal 
infiltrate surrounding each large airway was quanti-
fied as 0 — absent; 1 — minimal with a single layer 
clustering of inflammatory cells; 2 — moderate, with 
localised clustering of inflammatory cells; and, 3 — 
abundant, with large clusters of inflammatory cells 
extending from the airway towards adjacent alveoli. 
Two full sections were examined per each lung by 
three blinded observers. The final inflammatory score 
was the result of: [0*n airways with 0 score + 1*n 
airways with 1 score, 2*n airways with 2 score + 3*n 
airways with 3 score]/number of analysed airways.
Mucus hypersecretion. Lung samples were 
stained with PAS stain for the assessment of mucus 
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Figure 1. Mean linear intercept (MLI) and destructive index (DI). A. MLI was calculated by dividing the total length of all superimposed lines 
by the total number of intercepts with alveolar septal walls at the intersection point of two horizontal and vertical lines. B. DI was given as the 
percentage of destroyed alveoli of all the alveoli counted per section, using a microscopic point count technique. Scale bar = 100 µm.
Figure 2. Inflammatory score and mucus index. A. Inflammatory infiltration was scored as 0 — absent, 1 — minimal, with a single layer 
clustering of inflammatory cells; 2 — moderate, with localized clustering of inflammatory cells; and, 3 — abundant, with large clusters of 
inflammatory cells. Scale bar = 100 µm. B. Mucus index was evaluated by Periodic acid-Schiff (PAS) stain, where mucus stains light purple 
(red asterisk) and the cellular/glandular source stains blue (white arrow). Scale bar = 50 µm. 
hypersecretion. Mucus index (Fig. 2B) was developed 
to indicate the number of large airways positive for 
mucus (light purple colour) provided that the same 
airway showed positive staining for a cellular/glan-
dular source of mucus (blue colour). Two full sec-
tions were examined per each lung by three blinded 
observers.
Statistical analysis
Values shown are means ± standard error of 
mean. Paired Student t-test was used for compari-
son of mice body weights before and after experi-
mental exposures. Analysis of variance (ANOVA) with 
Bonferroni post hoc test was used for comparisons 
among the experimental groups (time points). Differ-
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ences were considered significant at p < 0.05. Data 
were analysed using the GraphPad Prism 5 software 
(GraphPad Software, Inc., USA).
RESULTS
Chronic WPS exposure leads to progressive loss 
of normal lung architecture devoid of substantial 
parenchymal inflammation
All mice survived the experimental exposures to WPS 
alone or in combination with SU. However, mean body 
weights of mice were generally lower at the end of ex-
perimental exposures in groups B through G (Table 1). 
A general overview of the resulting lung histological 
phenotype in the 7 experimental groups is shown in 
Figure 3. Chronic WPS exposure leads to progressive 
enlargement of airspaces, as assessed by MLI, culminat-
ing in a statistically significant increase at the 4-month 
time point (Fig. 4A). Furthermore, chronic WPS resulted 
in a time-dependent loss of normal alveolar architecture, 
as evaluated by the DI, reaching marked levels of de-
struction after 4 months of exposure (Fig. 4C). Contrary 
to the pathological picture of COPD in humans, lung 
interstitial inflammatory cell infiltration was minimal 
across all time points of chronic WPS exposure (Fig. 4E). 
Moreover, we sought to determine the presence of 
bronchial mucus, and if so the source of that mucus, in 
this mouse model, using the PAS stain. Mucus index, as 
given by the number of large airways positive for mucus 
and its cellular/glandular source, revealed no significant 
changes over time (Fig. 4G), perhaps highlighting the 
well-documented finding that rodents lack, or perhaps 
more accurately have much less numbers of, goblet cells 
and bronchial glands [16]. 
The combined exposure to chronic WPS and SU 
recapitulates major histopathological features of COPD
The simultaneous exposure to chronic WPS and SU 
for 1 month caused significant increases in both the 
MLI (Fig. 4B) and DI (Fig. 4D) compared to controls. 
These pathological changes were not observed in 
the SU alone group. Intriguingly, such morphometric 
changes were comparable in magnitude to those 
observed after 4 months of exposure to WPS alone. 
However, both SU alone and the combined use of WPS 
and SU for 1 month induced severe lung parenchy-
mal inflammation (Fig. 4F), indicating an additional 
phenotypic advantage over the use of chronic WPS 
alone as a preclinical model of COPD. The mucus 
index, nevertheless, remained consistently similar to 
those found across all time points of chronic WPS 
exposure (Fig. 4H).
DISCUSSION
This study preliminarily reports the successful in-
duction of COPD histopathological picture in mice by 
the combined and simultaneous exposure to WPS and 
the VEGFR blocker, SU. This novel preclinical model of 
COPD is primarily time and cost efficient, and exhibits 
major histopathological features of COPD, includ-
ing airspace enlargement, destruction of alveolar 
structure, and marked parenchymal inflammation. 
Furthermore, this study supported the hypothesis that 
pulmonary vascular endothelial dysfunction critically 
drives the onset of COPD, and works together with 
alveolar epithelial loss throughout the progression 
of the disease. 
The term “COPD” encompasses a group of dis-
eases that have in common a state of progressive 
airflow limitation, caused by the airways’ enhanced 
inflammatory responses to noxious stimuli [18]. Path-
ologically, COPD is marked by chronic inflammatory 
cell infiltration and pro-inflammatory mediators that 
lead to pulmonary epithelial cell death/apoptosis, and 
hence small airway remodelling and loss of alveoli 
[17]. Despite such basic knowledge, accumulating evi-
dence proved that none of the available therapies of 
COPD stops the ultimate fatal drop in lung function. 
It is possible, therefore, that exploring new dimen-
Table 1. Mean body weights (± standard error of mean) of mice at baseline and at the end of experimental exposure
Experimental group Weight at baseline [g] Weight after [g] Probability
A — Control 26.6 ± 1.5 – –
B — 1 month WPS 26.2 ± 1.1 25.3 ± 1 p = 0.01
C — 2 months WPS 27.3 ± 1.4 24.9 ± 1.1 p = 0.3
D — 3 months WPS 26.0 ± 1.7 25.1 ± 1.1 p = 0.6
E — 4 months WPS 27.2 ± 1.4 26.2 ± 1.7 p = 0.6
F — WPS + SU 27.6 ± 0.7 24.2 ± 0.7 p = 0.0008
G — SU alone 28.5 ± 0.5 25.8 ± 0.5 p = 0.007
SU — Semaxinib; WPS — waterpipe smoke
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Figure 3. Representative photomicrographs of haematoxylin and eosin-stained lungs of: 
controls (A); 1 month post waterpipe smoke (WPS) exposure (B); 2 months post WPS  
exposure (C); 3 months post WPS exposure (D); 4 months post WPS exposure (E);  
1 month of WPS exposure + Semaxinib (SU) (F); and SU alone (G). Scale bar = 100 µm.
sions in the pathology of COPD would offer insightful 
prognostic and therapeutic targets [8]. 
The Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) lists COPD as a preventable and treat-
able disease, despite being often complicated by exac-
erbations that worsen the patients’ outcome [15]. The 
“preventable” part of the definition pertains to the fact 
that smoking is the principal causative factor in COPD. 
Chronic WPS exposure was utilised as the source of 
tobacco smoke in this study. Waterpipe smoking is a pre-
dominant tobacco delivery method in both developed 
and developing countries. There is a cultural acceptance 
of waterpipe smoking, based on the misperception of its 
safety and lack of long-term health hazards, particularly 
cancers and respiratory problems [23]. Waterpipe smok-
ing is now considered the second most popular method 
of tobacco smoking in many developed countries [30], 
while surpassing cigarette smoking in 19 out of 24 
countries in the Eastern Mediterranean Region [23]. 
These high rates testify to the pervasiveness of the 
problem around the world. Importantly, several studies 
showed that the exposure pattern and dose of various 
components of tobacco smoke are very different be-
tween waterpipe and cigarette smoking [27, 34]. For 
instance, relative to 1 cigarette, a single session of wa-
terpipe involves inhaling 60–160 times smoke volume, 
1.7–2.3 times nicotine, 25–46 times tar, and 5–10 times 
CO [12, 40]. Despite such considerable differences, the 
long-term pulmonary consequences have not been fully 
elucidated. Thus, the current results can be of major 
clinical significance, as they underscore waterpipe smok-
ing as a potential risk for the development of COPD. 
The role of endothelial dysfunction in COPD pathol-
ogy was also explored in this study, based on the sub-
stantial evidence that changes in the endothelial milieu 
occur early in the disease process. Dinh-Xuan et al.; 1991 
[13], Peinado et al.; 1998 [32], Komurcuoglu et al.; 2003 
[24], and Barr et al.; 2007 [5] have all reported increased 
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markers of systemic endothelial dysfunction in mild 
COPD cases. These markers included microalbuminuria, 
impaired flow-mediated dilation, and decreased retinal 
vessel calibre. Kasahara et al. (2001) [20] reported that 
emphysematous lungs exhibit significant endothelial cell 
death and decreased expression of VEGF and VEGFR. 
Santos et al. (2003) [38] have also shown increased ex-
pression of VEGF in the pulmonary arteries of smokers 
with mild COPD. Additionally, Polatli et al. (2008) [33] re-
ported that COPD patients displayed microalbuminuria 
and increased plasma levels of the von Willibrand factor 
and fibrinogen during exacerbations. Such considerable 
evidence of involvement of endothelial dysfunction in 
COPD is the pivotal rationale for our study. 
The use of SU as an inducer of endothelial dysfunc-
tion in the current model builds on the previous report 
by Kasahara et al. (2000) [19], as they reported that SU 
injection in “healthy” rats causes alveolar cell apopto-
sis, emphysema, and pruning of the pulmonary arterial 
tree. VEGF, the chief member of hypoxia-inducible factor 
genes, is highly expressed in the lungs, and has been 
historically recognised as a “vascular permeability factor” 
[44]. Its major functions include: vascular endothelial cell 
growth and differentiation, vessel morphogenesis, and 
regulation of endothelial cell survival. VEGF also regulates 
growth and differentiation of type II pneumocytes, point-
ing to its critical role in the maintenance of “alveolar unit” 
normal functionality [43]. Blockade of such vital func-
tions by SU could add to the alveolar damage induced 
by WPS exposure, enhancing the induction of a COPD 
picture, most notably by stimulating lung inflammatory 
cell infiltration, as reported by Otsuki et al. [31].
This study manifests several limitations. While some 
of the major histopathological features of COPD were 
investigated, we have not elucidated the impact of these 
changes on lung mechanics and dynamics. This has hin-
dered the grading/staging of COPD in this model according 
to the GOLD criteria, which largely depend on pulmonary 
function tests in assessing severity of COPD in patients 
[15]. We have not explored any markers of pulmonary or 
systemic endothelial dysfunction in this model. Addition-
ally, the current sample size of animals used in this study 
is too small for a meaningful translation into a human risk 
assessment. However, we anticipate this report will open 
A B C D
Figure 4. A, B. Mean linear intercept; C, D. Destructive index; E, F. Inflammatory score; G, H. Mucus index in the seven experimental groups. 
*p< 0.05 vs. controls; +p < 0.05 vs. 1 month post waterpipe smoke (WPS); $p < 0.05 vs. 2 months post WPS; #p < 0.05 vs. 3 months 
post WPS; ^p < 0.05 vs. 4 months post WPS; @p < 0.05 vs. Semaxinib (SU) alone; m — month; CTRL — control.
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the door for further studies in the biomarkers research 
field. When correlated with the severity and outcomes of 
COPD, such biomarkers will be of significant diagnostic, 
prognostic, and therapeutic value in the future.
CONCLUSIONS
In conclusion, the combined exposure to chronic 
WPS and SU is a time and cost effective approach to 
preclinical modelling of COPD. The current results 
support the hypothesis that pulmonary vascular en-
dothelial dysfunction critically drives the onset of 
COPD, and works together with alveolar epithelial loss 
throughout the progression of the disease.  
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